These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25497475)

  • 1. A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.
    Pienaar E; Cilfone NA; Lin PL; Dartois V; Mattila JT; Butler JR; Flynn JL; Kirschner DE; Linderman JJ
    J Theor Biol; 2015 Feb; 367():166-179. PubMed ID: 25497475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
    Pienaar E; Dartois V; Linderman JJ; Kirschner DE
    BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
    Pienaar E; Linderman JJ; Kirschner DE
    PLoS One; 2018; 13(5):e0196322. PubMed ID: 29746491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.
    Pienaar E; Sarathy J; Prideaux B; Dietzold J; Dartois V; Kirschner DE; Linderman JJ
    PLoS Comput Biol; 2017 Aug; 13(8):e1005650. PubMed ID: 28817561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
    Koo MS; Manca C; Yang G; O'Brien P; Sung N; Tsenova L; Subbian S; Fallows D; Muller G; Ehrt S; Kaplan G
    PLoS One; 2011 Feb; 6(2):e17091. PubMed ID: 21364878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study.
    Lalande L; Bourguignon L; Maire P; Goutelle S
    J Theor Biol; 2016 Jun; 399():43-52. PubMed ID: 27059890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.
    Lenaerts A; Barry CE; Dartois V
    Immunol Rev; 2015 Mar; 264(1):288-307. PubMed ID: 25703567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiscale Model of Mycobacterium tuberculosis Infection Maps Metabolite and Gene Perturbations to Granuloma Sterilization Predictions.
    Pienaar E; Matern WM; Linderman JJ; Bader JS; Kirschner DE
    Infect Immun; 2016 May; 84(5):1650-1669. PubMed ID: 26975995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Within-host population dynamics of antibiotic-resistant M. tuberculosis.
    Alavez-Ramírez J; Castellanos JR; Esteva L; Flores JA; Fuentes-Allen JL; García-Ramos G; Gómez G; López-Estrada J
    Math Med Biol; 2007 Mar; 24(1):35-56. PubMed ID: 17060491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
    Nikonenko BV; Protopopova M; Samala R; Einck L; Nacy CA
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1563-5. PubMed ID: 17242141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity in tuberculosis.
    Cadena AM; Fortune SM; Flynn JL
    Nat Rev Immunol; 2017 Nov; 17(11):691-702. PubMed ID: 28736436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection.
    Marino S; Cilfone NA; Mattila JT; Linderman JJ; Flynn JL; Kirschner DE
    Infect Immun; 2015 Jan; 83(1):324-38. PubMed ID: 25368116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice.
    Dutta NK; Bruiners N; Zimmerman MD; Tan S; Dartois V; Gennaro ML; Karakousis PC
    J Infect Dis; 2020 Mar; 221(7):1079-1087. PubMed ID: 31605489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment.
    Beamer G; Major S; Das B; Campos-Neto A
    Am J Pathol; 2014 Dec; 184(12):3170-5. PubMed ID: 25451154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.